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1269.79] vs PBO:2.36ng/mL [range 0.02; 2254.50]). Lastly, AAP significantly delayedmed
time to PSAprogression as compared to PBO (33.2mo vs 7.4mo, respectively; HR: 0.3,
p< 0.0001) and the time to PSA progression strongly correlatedwith rPFS (Kendall’s tau¼
0.9211) andOS (Kendall’s tau¼ 0.666).
Conclusions: Treatment of high-risk mHSPC with ADTþAAP demonstrates a signifi-
cant depth of PSA response that strongly correlates with long-term outcomes of rPFS
and OS.
Clinical trial identification:NCT01715285.
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Background: A comprehensive assessment of biopsies frommetastatic prostate cancer
(mPCa) patients (pts) may identify a molecular subset of pts susceptible for immune
checkpoint (IC) blockade (ICB).
Methods: 148 biopsies and germline DNA from 145mPCa pts were whole genome
sequenced (WGS) at an average of 114x and 38x. Tumour mutational (mut) burden
(TMB) was defined as number of somatic single nucleotide variants and InDels perMb
of the genome, knownmut signatures (Alexandrov, Nature 2013) extracted by non-
negative least squares regression as well as recurrent mutations reported in mismatch
repair (MMR) pts (Kim, Cell 2013). Selected pts with high TMBwere further evaluated
for; (a) MMR protein expression; (b) multiplex intratumoural (IT) immune cell phe-
notyping (VECTRA); (c) multiplex IC expression (VECTRA); (d) 8-color flow cytome-
try blood immune cell phenotyping, with high TMB pts compared with low TMB pts.
Pts receiving anti-PD-1 ICB had additional immune phenotyping at C2, C3, C4 and at
progression; 3 pts had post-progression biopsies analyzed.
Results: The median TMBwas 2.9 (IQR 2.2 - 3.9); 12 pts (8.3%) had high TMB (>10
mut/Mb). In 11/12 pts with high TMB, correspondingMMR deficiency (MMRd) sig-
natures (6, 15, 20 and 21) were identified. Recurrent mut inMMR genes were detected
MSH2/MSH6,MSH3, MLH1; other recurrent mut were in POLE, and frameshift mut
enriched (p< 0.001) in genes including TGFBR2, CLOCK, RPL22 and JAK1.
Immunohistochemistry confirmedMMRd in 6/6 biopsies and inmatched primary tis-
sue in 5/5 evaluable pts. Five pts were referred for germline testing without MMRmut.
A trend for increased IT CD3þ cells were seen inMMRd (p¼ 0.06); no relation was
found between TMB and tumour PD-L1 expression. Pts were treated with anti-PD-1
ICB, with PSA>50% decline of 57% of hTMB pts (n¼ 7), and a significant decline in
circulating T-cell populations during ICB, including CD4þPD-1þ (p¼ 0.02) and
CD8þPD-1þ (p¼ 0.007). Response rate, duration of response, genomic and immune
correlates will be presented for pts with low and high TMB.
Conclusions: 8% ofmPCa pts display a high TMB with recurrent somatic mut in
MMR genes and POLE.MMRd appears early in PCa evolution. High TMB pts witness
a high response rate to monotherapy anti-PD-1 ICB.
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Background: PSMA is selectively overexpressed in advanced PC with upregulation by
androgen receptor (AR) pathway dysregulation; limited expression in other organs. PC
is radiosensitive with dose-response data. Dose-fractionation may allow delivery of
higher total doses with less radioresistance than doses several weeks to months apart.
Small molecule PSMA inhibitor ligands can be successfully radiolabeled and have been
used for imaging and treatment, but no dose-escalation study has been performed.
Methods: Progressive mCRPC following at least 1 potent AR-targeted agent (e.g. abi/
enza) and docetaxel (or unfit/refuse chemo) without limit of # prior therapies provided
adequate organ function, ECOGperformance status 0-2, andwithout preselection for
PSMA expression were enrolled. Treatment was a single cycle of fractionated dose 177Lu-
PSMA-617 onD1 andD15 starting at 7.4 GBqwith planned escalation up to 22.2 GBq in
modified 3þ 3 dose-escalation. Primary endpoint is determination of dose limiting tox-
icity (DLT) and recommended phase 2 dose (RP2D)with secondary efficacy endpoints.
Pre- and post-treatment 68Ga-PSMA11 PET/CT and post-treatment 177Lu-PSMA-617
imaging was performed in addition to standard serial CT and bone scans.
Results: 29men with median age 70 (range 56-87), median PSA 98.9 (range 6-2222)
were treated. 93% with bone, 25% node, 14% lung, 7% liver, 7% other visceral metasta-
ses. 52%with at least 1 chemo, 45%>1 prior potent AR therapy, 17%with Ra223, 10
sip-T, 3% 177Lu-J591. No DLT was seen at any planned dose-level. With follow up
ongoing, 41% with>50% PSA decline. Of 14 with paired CTC counts (CellSearch),
64% decreased, 14% stable, 14% increased (with 28.6% undetectable at 12 weeks).
Adverse events include 55% xerostomia, 27.6% fatigue, 27.6% nausea, 27.6% thrombo-
cytopenia, 20.7% anemia, 17.2% back pain. All had some PSMA uptake on imaging,
with median (range) SUVmax 25 (4-119) bone, 32 (7-111) node, 10 (3-16) visceral.
Conclusions:Dose-escalation of 177Lu-PSMA-617 is safe up to 22.2 GBq per cycle with
fractionated dosing, with promising early efficacy and tolerability signals. Enrollment
to the phase 2 study at RP2D will provide additional efficacy and toxicity data.
Clinical trial identification:NCT03042468.
Legal entity responsible for the study:Weill Cornell Medical College.
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Background: Intraductal carcinoma of the prostate (IDC-P) is an adverse prognostica-
tor of prostate cancer (PCa). However, the role of IDC-P proportion and architectural
patterns in patient outcome remain unclear.
Methods:Data of 644 de novometastatic PCa (mPCa) patients between 2010-2017
were retrospectively analyzed. IDC-P was identified from 12-core prostate biopsy.
IDC-P proportion were calculated. IDC-P were classified into two architectural pat-
terns according to the 2016WHO classification: pattern-1 (loose cribriform or micro-
papillary) and pattern-2 (solid or dense cribriform). Propensity-score matching (PSM)
was conducted to balance the baseline characteristics between patients with and
without IDC-P. Kaplan-Meier curves and COX regression were utilized in survival
analysis. The endpoints were castration-resistant PCa free survival (CFS) and overall
survival (OS).
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